If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
==== p27 ==== Another gene that is a target of gene amplification is SKP2. SKP2 is an F-box protein with a role in substrate recognition for ubiquitylation and degradation. SKP2 targets p27Kip-1, an inhibitor of cyclin-dependent kinases (CDKs). CDKs2/4 partner with the cyclins E/D, respectively, forming a family of cell cycle regulators which control cell cycle progression through the G1 phase. Low level of p27Kip-1 protein is often found in various cancers and is due to overactivation of ubiquitin-mediated proteolysis through overexpression of SKP2.
Sanders attended high school with economist Walter Block. When he was 19, his mother died at age 47, following failed cardiac surgery. His father died two years later, in 1962, at age 57. Sanders studied at Brooklyn College for a year in 1959–1960 before transferring to the University of Chicago and graduating with a Bachelor of Arts degree in political science in 1964. In later interviews, Sanders described himself as a mediocre college student because the classroom was "boring and irrelevant" and said he viewed community activism as more important to his education.
== SMN complex == SMN complex refers to the entire multi-protein complex involved in the assembly of snRNPs, the essential components of spliceosomal machinery. The complex, apart from the "proper" survival of motor neuron protein, includes at least six other proteins (gem-associated protein 2, 3, 4, 5, 6 and 7.
Official website About Hooters – the Atlanta-based chain's information page Original Hooters – the Clearwater-based founders sub-chain Transfer of "Hooters" brand from Clearwater to Atlanta, a March 2001 article from Atlanta Business Chronicle Sexual Harassment Retaliation Lawsuit, from The Smoking Gun Fortune magazine feature on Hooters Hooters All Set to Open in Phuket Thailand
In Australia, New Zealand, and the United States, it is considered an analog of other illegal drugs and can be controlled under laws similar to the US Federal Analog Act. In September 2011, the US temporarily classified mephedrone as a Schedule I drug, with the classification taking effect in October 2011. This was made permanent in July 2012 with the passage of the Synthetic Drug Abuse Prevention Act (SDAPA).
Sources: en.wikipedia.org
=== Blue Shift === On February 16, 2021, HECU Collective announced that they would be taking a break from their mod Black Mesa: Azure Sheep and were now focusing on a remake of Half-Life: Blue Shift. Unlike another remake in progress, Guard Duty by Tripmine Studios, the mod utilizes assets from Black Mesa instead of creating it from scratch and is released in chapters. The mod began development after a previous attempt at a Blue Shift remake, Insecurity, was abandoned. Half of the members transitioned to working on the mod while the other half continued work on Azure Sheep. The first of the game's eight chapters was released on March 16, 2021, and as of November 2024, five of the eight total chapters have been released.
Certain serotonergic psychedelics and related non-hallucinogenic drugs, acting as serotonin 5-HT2A receptor agonists, have been reported to have mild stimulant and/or "psychic energizing" (i.e., acute antidepressant) effects, both in animals and humans. These effects are often present at low or sub-hallucinogenic doses. Psychedelics are also known to promote wakefulness or cause insomnia. Psychedelic and related drugs that have been reported to produce stimulant effects include the phenethylamines 2,5-DMA (DOH), DOM, DOET, DOPR, DON, MTFEM, Ariadne (4C-DOM; BL-3912; Dimoxamine), 2C-B, 2C-D, 2C-G-N, and ASR-2001 (2CB-5PrO), and the tryptamines 5-MeO-DiPT and 5-MeO-MiPT, among others. The lysergamide LSD has also been reported to have mild stimulant effects. Conversely, psilocybin does not seem to produce the same stimulant effects. The non-hallucinogenic Ariadne was under development as a potential pharmaceutical drug to take advantage of such effects in the treatment of conditions like depression in the 1970s, and reached phase 3 clinical trials for such indications, but was shelved reportedly for strategic economic reasons. ASR-2001, which is likewise non-hallucinogenic, is under development for use as a stimulant-like medication for treatment of psychiatric disorders. Serotonin 5-HT2A receptor agonists have been found to increase dopamine levels in brain areas like the frontal cortex, striatum, and nucleus accumbens in animal studies.
Fluorescent D-amino acids (FDAAs) are D-amino acid derivatives whose side-chain terminal is covalently coupled with a fluorophore molecule. FDAAs incorporate into the bacterial peptidoglycan (PG) in live bacteria, resulting in strong peripheral and septal PG labeling without affecting cell growth. They are featured with their in-situ incorporation mechanisms which enable time-course tracking of new PG formation. To date, FDAAs have been employed for studying the cell wall synthesis in various bacterial species (both gram-positives and gram-negatives) through different techniques, such as microscopy, mass spectrometry, flow cytometry.
New Zealand ordered 370 P-51 Mustangs to supplement its F4U Corsairs in the Pacific Ocean Areas theater. Scheduled deliveries were for an initial batch of 30 P-51Ds, followed by 137 more P-51Ds and 203 P-51Ms. The original 30 were being shipped as the war ended in August 1945; these were stored in their packing cases, and the order for the additional Mustangs was canceled. In 1951, the stored Mustangs entered service in 1 (Auckland), 2 (Wellington), 3 (Canterbury), and 4 (Otago) squadrons of the Territorial Air Force (TAF). The Mustangs remained in service until they were prematurely retired in August 1955 following a series of problems with undercarriage and coolant-system corrosion problems. Four Mustangs served on as target tugs until the TAF was disbanded in 1957. RNZAF pilots in the Royal Air Force also flew the P-51 and at least one New Zealand pilot scored victories over Europe while on loan to a USAAF P-51 squadron. Nicaragua The Nicaraguan National Guard purchased 26 P-51D Mustangs from Sweden in 1954 and later received 30 P-51D Mustangs from the US together with two TF-51 models from MAP after 1954. All aircraft of this type were retired from service by 1964. Philippines
== External links == Protein Structure Initiative (PSI) PSI:Biology Funded Centers and Grants Structural Biology Knowledgebase PSI:Biology-Materials Repository Open Protein Structure Annotation Network (TOPSAN), a wiki for annotation of protein structures determined by the PSI
Sources: en.wikipedia.org
In other instances, molecular interactions between gas molecules previously adsorbed on a solid surface form significant interactions with gas molecules in the gaseous phases. Hence, adsorption of gas molecules to the surface is more likely to occur around gas molecules that are already present on the solid surface, rendering the Langmuir adsorption isotherm ineffective for the purposes of modelling. This effect was studied in a system where nitrogen was the adsorbate and tungsten was the adsorbent by Paul Kisliuk (1922–2008) in 1957. To compensate for the increased probability of adsorption occurring around molecules present on the substrate surface, Kisliuk developed the precursor state theory, whereby molecules would enter a precursor state at the interface between the solid adsorbent and adsorbate in the gaseous phase. From here, adsorbate molecules would either adsorb to the adsorbent or desorb into the gaseous phase. The probability of adsorption occurring from the precursor state is dependent on the adsorbate's proximity to other adsorbate molecules that have already been adsorbed. If the adsorbate molecule in the precursor state is in close proximity to an adsorbate molecule that has already formed on the surface, it has a sticking probability reflected by the size of the SE constant and will either be adsorbed from the precursor state at a rate of kEC or will desorb into the gaseous phase at a rate of kES.
The Ukrainian Ground Forces announced that Andrii Kovalchuk, the head of its Operational Command South, had been appointed as head of the Odesa Military Academy, while Serhii Litvinov, the head of its Operational Command West, had been appointed as deputy head of the National Defence University of Ukraine. They were replaced in their previous positions by Major General Hennadii Shapovalov and Brigade General Volodymyr Shvediuk, respectively.
A medical laboratory scientist (MLS), clinical laboratory scientist (CLS), or medical technologist (MT) is a licensed healthcare professional who performs diagnostic testing of body fluids, examples: blood, urine, sputum and other body tissue. The medical technologist is tasked with releasing the patient's results to aid in further treatment. The scope of a medical laboratory scientist's work begins with the receipt of patient or client specimens, and finishes with the delivery of test results to physicians and other healthcare providers. The utility of clinical diagnostic testing relies squarely on the validity of test methodology. To this end, much of the work done by medical laboratory scientists involves ensuring specimen quality, interpreting test results, data-logging, testing control products, performing calibration, maintenance, validation, and troubleshooting of instrumentation as well as performing statistical analyses to verify the accuracy and repeatability of testing. Medical laboratory scientists may also assist healthcare providers with test selection and specimen collection and are responsible for prompt verbal delivery of critical lab results. Medical laboratory scientists in healthcare settings also play an important role in clinical diagnosis; some estimates suggest that up to 70% of medical decisions are based on laboratory test results and MLS contributions affect 95% of a health system's costs.
== Adverse effects == Data from clinical trials submitted to regulatory authorities showed that rimonabant caused depressive disorders or mood alterations in up to 10% of subjects and suicidal ideation in around 1%, and in Europe it was contraindicated for people with any psychiatric disorder, including clinical depression. Data from a large, randomized, clinical trial (CRESCENDO) with > 9,000 patients receiving rimonabant treatment demonstrated a rate of psychiatric adverse events (anxiety, depression, depressed mood, or insomnia) of greater than 30%. Additionally, nausea and upper respiratory tract infections were very common adverse effects (occurring in more than 10% of people); common adverse effects (occurring in between 1% and 10% of people) included gastroenteritis, anxiety, irritability, insomnia and other sleep disorders, hot flushes, diarrhea, vomiting, dry or itchy skin, tendonitis, muscle cramps and spasms, fatigue, flu-like symptoms, and increased risk of falling. The FDA's advisory committee concurred with concerns raised by the review divisions. Based on human and on animal data, it appeared that the therapeutic window was narrow. EMA postmarketing surveillance data suggested that the risk of psychiatric disorders in people taking rimonabant was doubled.
=== Angiofibromas === Sirolimus has been used as a topical treatment of angiofibromas with tuberous sclerosis complex (TSC). Facial angiofibromas occur in 80% of patients with TSC, and the condition is very disfiguring. A retrospective review of English-language medical publications reporting on topical sirolimus treatment of facial angiofibromas found sixteen separate studies with positive patient outcomes after using the drug. The reports involved a total of 84 patients, and improvement was observed in 94% of subjects, especially if treatment began during the early stages of the disease. Sirolimus treatment was applied in several different formulations (ointment, gel, solution, and cream), ranging from 0.003 to 1% concentrations. Reported adverse effects included one case of perioral dermatitis, one case of cephalea, and four cases of irritation. In April 2022, sirolimus was approved by the FDA for treating angiofibromas.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.